Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC Jr, Oram D, Jacobs IJ.

J Clin Oncol. 2005 Nov 1;23(31):7919-26.

PMID:
16258091
2.

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I.

Lancet Oncol. 2009 Apr;10(4):327-40. doi: 10.1016/S1470-2045(09)70026-9.

3.

A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.

Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC Jr.

Cancer. 2013 Oct 1;119(19):3454-61. doi: 10.1002/cncr.28183.

4.

Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.

Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ.

BJOG. 2014 Dec;121 Suppl 7:35-9. doi: 10.1111/1471-0528.13211.

5.

Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.

Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I.

J Clin Oncol. 2015 Jun 20;33(18):2062-71. doi: 10.1200/JCO.2014.59.4945.

6.

Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.

Hensley ML, Robson ME, Kauff ND, Korytowsky B, Castiel M, Ostroff J, Hurley K, Hann LE, Colon J, Spriggs D.

Gynecol Oncol. 2003 Jun;89(3):440-6.

PMID:
12798709
7.

The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.

van Nagell JR Jr, DePriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, Kryscio RJ.

Gynecol Oncol. 2000 Jun;77(3):350-6.

PMID:
10831341
8.

Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.

9.

Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).

Sharma A, Apostolidou S, Burnell M, Campbell S, Habib M, Gentry-Maharaj A, Amso N, Seif MW, Fletcher G, Singh N, Benjamin E, Brunell C, Turner G, Rangar R, Godfrey K, Oram D, Herod J, Williamson K, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Fourkala EO, Ryan A, Parmar M, Jacobs I, Menon U.

Ultrasound Obstet Gynecol. 2012 Sep;40(3):338-44. doi: 10.1002/uog.12270.

10.

Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening.

Drescher CW, Nelson J, Peacock S, Andersen MR, McIntosh MW, Urban N.

Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):600-6.

11.

Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.

Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH, Jacobs IJ.

BJOG. 2000 Feb;107(2):165-9.

12.

The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?

Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, Salvagno GL, Franchi M, Lippi G, Guidi GC.

Clin Chem Lab Med. 2011 Mar;49(3):521-5. doi: 10.1515/CCLM.2011.075.

PMID:
21288178
13.

HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.

Richards A, Herbst U, Manalang J, Pather S, Saidi S, Tejada-Berges T, Tan K, Williams P, Carter J.

Aust N Z J Obstet Gynaecol. 2015 Oct;55(5):493-7. doi: 10.1111/ajo.12363.

PMID:
26172511
14.

Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.

Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs C, Armstrong DK, Buys SS, Rodriguez GC, Horowitz IR, Berchuck A, Daly MB, Domchek S, Cohn DE, Van Le L, Schorge JO, Newland W, Davidson SA, Barnes M, Brewster W, Azodi M, Nerenstone S, Kauff ND, Fabian CJ, Sluss PM, Nayfield SG, Kasten CH, Finkelstein DM, Greene MH, Lu K.

Cancer Prev Res (Phila). 2011 Sep;4(9):1401-8. doi: 10.1158/1940-6207.CAPR-10-0402.

15.

Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.

Li F, Tie R, Chang K, Wang F, Deng S, Lu W, Yu L, Chen M.

BMC Cancer. 2012 Jun 19;12:258. doi: 10.1186/1471-2407-12-258.

16.

A randomized study of screening for ovarian cancer: a multicenter study in Japan.

Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, Kanayama S, Shigetomi H, Haruta S, Tsuji Y, Ueda S, Kitanaka T.

Int J Gynecol Cancer. 2008 May-Jun;18(3):414-20.

PMID:
17645503
17.

Factors influencing serum CA125II levels in healthy postmenopausal women.

Pauler DK, Menon U, McIntosh M, Symecko HL, Skates SJ, Jacobs IJ.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):489-93.

18.

Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women.

Jeyarajah AR, Ind TE, Skates S, Oram DH, Jacobs IJ.

Cancer. 1999 May 1;85(9):2068-72.

PMID:
10223249
19.

Screening postmenopausal women for ovarian cancer: a systematic review.

Fung MF, Bryson P, Johnston M, Chambers A; Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group..

J Obstet Gynaecol Can. 2004 Aug;26(8):717-28. Review.

PMID:
15307976
20.

A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study.

Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):594-604. doi: 10.1158/1055-9965.EPI-07-2703.

Items per page

Supplemental Content

Support Center